Related Experiment Video

Updated: Aug 26, 2026

In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension?

Cindy J M Loomans1, Huy H Dao, Anton J van Zonneveld

  • 1Department of Vascular Medicine, University Medical Center of Utrecht, G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

Current Hypertension Reports
|February 20, 2004
PubMed

Insights

Essential hypertension may be treated by enhancing angiogenesis, the formation of new blood vessels. Endothelial progenitor cells show promise in improving capillary rarefaction and arterial stiffness in hypertensive patients.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Hypertension Research

Background:

  • Hypertension is a major modifiable risk factor for cardiovascular disease (CVD).
  • Despite advances, blood pressure control doesn't fully prevent hypertension-related end-organ damage.
  • Reduced angiogenesis is emerging as a potential CVD risk factor.

Purpose of the Study:

  • To review the therapeutic potential of angiogenesis in essential hypertension.
  • To explore the role of endothelial progenitor cells in hypertension.
  • To investigate angiogenesis's impact on capillary rarefaction and arterial stiffness.

Main Methods:

  • Literature review on angiogenesis and hypertension.
  • Analysis of studies on endothelial progenitor cells (EPCs) and vascular function.
  • Discussion of therapeutic strategies involving angiogenesis induction.

Main Results:

  • Pharmacologic and stem cell strategies can induce angiogenesis, benefiting ischemic vascular disease.
  • Limited research exists on angiogenesis's therapeutic role in essential hypertension.
  • EPCs may modulate angiogenesis, potentially improving hypertension-related vascular changes.

Conclusions:

  • Angiogenesis induction is a potential therapeutic avenue for essential hypertension.
  • Endothelial progenitor cells may play a key role in managing hypertension-related vascular dysfunction.
  • Targeting angiogenesis could improve capillary rarefaction and arterial stiffness in hypertensive patients.

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 200007:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...